Megace

Megestrol acetate, the active ingredient in Megace, is a progestin presented as an oral tablet for oral use. It is used to stimulate appetite and to treat hormone‑responsive cancers such as certain breast and endometrial tumors, as well as to manage cachexia associated with cancer or AIDS.

GNH USA supplies Megace as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Megace is employed in clinical pathways that address severe weight loss and hormone‑responsive malignancies.

Cachexia associated with cancer or AIDS: improves appetite and helps stabilize body weight. Weight loss in chronic illness: increases caloric intake and promotes modest weight gain. Hormone‑responsive breast cancer: provides antineoplastic activity by modulating progesterone receptors. Endometrial cancer: used as part of hormonal therapy to inhibit tumor growth.

Megace may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Weight gain - Edema - Fatigue

Serious or Rare Side Effects: - Thromboembolic events (deep‑vein thrombosis, pulmonary embolism) - Adrenal insufficiency - Severe hyperglycemia or Cushingoid appearance

When prescribing Megace, clinicians should consider several safety measures.

Monitor blood glucose: patients may develop hyperglycemia or diabetes. Assess thromboembolic risk: evaluate history of clotting disorders before initiating therapy. Evaluate adrenal function: prolonged use can suppress the hypothalamic‑pituitary‑adrenal axis. Review concomitant hormone therapy: may enhance progestogenic effects. Adjust dose in hepatic impairment: liver dysfunction can increase drug exposure. Store at ambient temperature: keep in original container, protect from moisture and light.

Megace interacts with several medicines; awareness of the interaction level guides management.

Major Interactions (Avoid): - Warfarin and other anticoagulants: increased risk of bleeding. - CYP3A4 inducers (e.g., rifampin, phenytoin): reduced efficacy of Megace. - Antidiabetic agents (insulin, sulfonylureas): enhanced hypoglycemic effect.

Moderate Interactions (Monitor Closely): - Corticosteroids: additive glucocorticoid effects may raise infection risk. - Hormonal contraceptives: may decrease contraceptive effectiveness.